eletriptan hydrobromide
eletriptan hydrobromide
Pharmacologic class: 5-hydroxytryptamine-1 (5-HT1) receptor agonist
Therapeutic class: Antimigraine agent
Pregnancy risk category C
Action
Binds with serotonin 5-HT1B receptors on intracranial blood vessels and serotonin 5-HT1D receptors on sensory nerve endings, constricting cranial arteries and thereby relieving migraine
Availability
Tablets: 20 mg, 40 mg
Indications and dosages
➣ Migraine with or without aura
Adults: Initially, 20 to 40 mg P.O.; may repeat in 2 hours if headache returns after initial improvement. Maximum recommended single dosage is 40 mg.
Contraindications
• Hypersensitivity to drug
• Basilar and hemiplegic migraine
• Severe hepatic disease
• Ischemic heart disease
• Peripheral vascular disease
• Cerebrovascular syndromes
• Uncontrolled hypertension
• Ischemic bowel disease
• Within 24 hours of another serotonin agonist or ergot-type drug
Precautions
Use cautiously in:
• hepatic or renal impairment, diabetes mellitus, hypercholesterolemia, cardiac disorders
• pregnant or breastfeeding patients
• children.
Administration
• Give first dose as soon as migraine symptoms arise.
See Be aware that first dose should be given under close supervision to patients with coronary artery disease.
• If headache improves but then recurs, give second dose at least 2 hours after first.
• Be aware that drug's safety in treating an average of more than three headaches within a 30-day period has not been established.

Adverse reactions
CNS: dizziness, insomnia, drowsiness, headache, fatigue, anxiety, paresthesia, asthenia,cerebrovascular ischemia
CV: chest pain, palpitations, hypertension,cardiovascular ischemia
GI: nausea, vomiting, diarrhea, dry mouth
Musculoskeletal: muscle weakness
Respiratory: chest tightness or pressure
Skin: flushing
Other: hot or cold sensation
Interactions
Drug-drug. Antihistamines, ergotamine, ergot derivatives: increased vasospastic effects
CYP450-3A4 inhibitors (such as clarithromycin, ketoconazole, propranolol): increased eletriptan blood level
MAO inhibitors: increased eletriptan effects
Patient monitoring
• Monitor vital signs and assess for chest pain, tightness, or pressure.
Patient teaching
• Instruct patient to take first dose as soon as migraine symptoms occur. If headache improves but then recurs, advise him to take second dose at least 2 hours after first.
• Caution patient to avoid driving and other hazardous activities until drug no longer affects concentration and alertness.
• Tell patient to report chest pain, pressure, or tightness.
• Inform patient that drug won't prevent migraines and isn't effective against other headache types.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs mentioned above.